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Treatment	  of	  food	  allergy	  consists	  of	  the	  avoidance	  of	  
the	  speciﬁc	  allergenic	  food.	  However,	  the	  possibility	  of	  
cross-­‐reac<vity	  with	  other	  food	  sources	  makes	  this	  
prac<ce	  some<mes	  ineﬀec<ve.	  The	  use	  of	  
hypoallergenic	  molecules	  with	  the	  ability	  to	  s<mulate	  
T	  cells	  may	  be	  a	  promising	  tool	  for	  speciﬁc	  
immunotherapy.	  	  
INTRODUCTION	  
MATERIAL	  AND	  METHODS	  
RESULTS	  AND	  CONCLUSIONS	  
IgE	  binding	  capaci<es	  of	  pru	  p	  3.2	  and	  pru	  p3.3	  were	  
reduced	  in	  most	  tested	  sera	  (9-­‐96%),	  and	  conﬁrmed	  
by	  inhibi<on	  ELISA	  assays	  with	  a	  serum	  pool	  from	  











Regarding	  IgG4	  epitopes,	  Mut3	  showed	  decreased	  





The	  in	  vivo	  allergic	  response	  was	  signiﬁcantly	  lower	  for	  
pru	  p	  3.1	  and	  pru	  p	  3.2,	  and	  nega<ve	  for	  pru	  p	  3.3,	  













The	  aim	  was	  to	  produce	  hypoallergenic	  Pru	  p	  3,	  peach	  
LTP,	  mutants	  by	  site-­‐directed	  mutagenesis,	  in	  residues	  
involved	  in	  B-­‐epitopes.	  
Three	  Pru	  p	  3	  mutants	  were	  produced	  in	  Pichia	  









The	  IgE,	  IgG1	  and	  IgG4-­‐binding	  capaci<es	  of	  the	  three	  
of	  them	  were	  tested	  by	  direct	  and	  inhibi<on	  ELISA	  
assays	  with	  pa<ents’	  sera.	  Their	  allergenic	  capacity	  
was	  evaluated	  by	  skin	  prick	  test.	  The	  T-­‐cell	  response	  
induced	  by	  these	  an<gens	  was	  compared	  with	  that	  of	  
the	  wild	  type.	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Reduc<on	  	  
pru	  p	  3.1	  25%	  (range	  1-­‐59%)	  
pru	  p	  3.2	  24%	  (range	  0-­‐46%)	  
pru	  p	  3.3	  65%	  (range	  32-­‐93%)	  
Reduc<on	  	  
pru	  p	  3.1	  21%	  (range	  2-­‐43%)	  
pru	  p	  3.2	  1%	  (range	  0-­‐4%)	  
pru	  p	  3.3	  29%	  (range	  0-­‐62%)	  
Reduc<on	  	  
pru	  p	  3.1	  12%	  (range	  0-­‐51%)	  
pru	  p	  3.2	  19%	  (range	  0-­‐57%)	  
pru	  p	  3.3	  72%	  (range	  58-­‐97%)	  
T-­‐cell	  ac<va<on	  capaci<es	  
were	  similar	  for	  the	  natural	  
protein	  and	  the	  mutants.	  All	  
these	  data	  suggest	  that	  these	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